Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.90    0.00 (0.00%)
Bid:
1.80
Ask:
2.00
Spread: 0.20 (11.111%)
Market Cap: £8.30m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Form 8.5 (EPT/RI)-Renalytix Plc

17 Jun 2024 10:08

Form 8.5 (EPT/RI)-Renalytix Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Investec Bank plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeRenalytix plc
(c) Name of the party to the offer with which exempt principal trader is connected:Investec is Joint Broker to Renalytix plc
(d) Date dealing undertaken: 14th June 2024
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid / received (pence)Lowest price per unit paid / received (pence)
Ordinary Shares Purchase 21,888 18.98 18.725

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
     

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
    

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
 

Date of disclosure:17th June 2024
Contact name:Abhishek Gawde
Telephone number:+91 9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

Date   Source Headline
1st Apr 20197:00 amRNSPublication of confirmation study results
25th Mar 20197:00 amRNSHalf-year Report
22nd Mar 20197:00 amRNSRenalytixAI Forms Core Investigator Group
12th Mar 20197:00 amRNSInvestor briefing
14th Feb 20197:00 amRNSAppointment of Nomad and Joint Broker
13th Feb 20197:00 amRNSJoint venture partnership agreement with AKESOgen
6th Feb 20197:00 amRNSRenalytixAI Expands Leadership Team
23rd Jan 20197:00 amRNSInitiates Clinical Validation Study
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
2nd Jan 20197:00 amRNSExercise of Option for Exclusive License
20th Dec 20185:20 pmRNSDirector/PDMR Shareholding
20th Dec 20187:01 amRNSPlanned appointment of joint broker & of NOMAD
19th Dec 20186:28 pmRNSDirector Dealing
17th Dec 20181:30 pmRNSHolding(s) in Company
9th Nov 201810:30 amRNSHolding(s) in Company
8th Nov 20184:50 pmRNSHolding(s) in Company
8th Nov 20187:00 amRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSRENX Admission to AIM and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.